Identifying a combination of biomarkers to predict treatment response to nabilone for the treatment of agitation in Alzheimer's disease – a secondary analysis
Gardado en:
| Publicado en: | Alzheimer's & Dementia vol. 21 (Dec 1, 2025) |
|---|---|
| Autor Principal: | |
| Outros autores: | , , , , , , , , |
| Publicado: |
John Wiley & Sons, Inc.
|
| Materias: | |
| Acceso en liña: | Citation/Abstract Full Text - PDF |
| Etiquetas: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3286852212 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1552-5260 | ||
| 022 | |a 1552-5279 | ||
| 024 | 7 | |a 10.1002/alz70857_103580 |2 doi | |
| 035 | |a 3286852212 | ||
| 045 | 0 | |b d20251201 | |
| 100 | 1 | |a Wang, Hui Jue (Janet) |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 245 | 1 | |a Identifying a combination of biomarkers to predict treatment response to nabilone for the treatment of agitation in Alzheimer's disease – a secondary analysis | |
| 260 | |b John Wiley & Sons, Inc. |c Dec 1, 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background Agitation is a challenging neuropsychiatric symptom (NPS) of Alzheimer's disease (AD). A crossover trial found that nabilone significantly improved agitation in AD patients over 6 weeks compared to placebo. Here, we aim to identify a combination of biomarkers that could be used to predict treatment response to nabilone for AD‐associated agitation. Methods Agitation was assessed using the Cohen‐Mansfield Agitation Inventory (CMAI). Serum concentrations of 13 markers were measured. Linear regression was used to estimate change in CMAI due to nabilone for the high and low groups of each biomarker. Biomarkers with a difference ≥8.5 points between groups were included in subsequent multivariate models. Index scores representing the difference between expected CMAI change given nabilone and placebo were calculated and divided into quartiles. Mean difference in CMAI change and 95% confidence intervals were estimated via bootstrapping. Results Four of the 13 biomarkers which met criteria specified above were included in multivariate modeling (n = 67). Nabilone was more efficacious in participants with higher IL‐6 (estimated change in CMAI ‐15.4, standard error (SE) 5.6), higher ISO‐8 (‐14.4, SE=5.0), higher 24S‐OHC (‐14.2, SE=4.1), and lower clusterin (‐14.6, SE=4.4). Participants in Q1 of index scores demonstrated better response to nabilone with a mean difference in CMAI change of ‐20.9 (95% CI: ‐31.8, ‐9.2), while those in Q2‐4 showed no difference between treatments. Conclusions Participants with higher levels of inflammation, oxidative stress, and cholesterol metabolite were more likely to benefit from nabilone for agitation in AD. A combination of biomarkers could help in distinguishing responders and non‐responders to nabilone. | |
| 653 | |a Indexes | ||
| 653 | |a Serum | ||
| 653 | |a Alzheimer's disease | ||
| 653 | |a Bootstrapping | ||
| 653 | |a Psychiatry | ||
| 653 | |a Cholesterol | ||
| 653 | |a Treatment methods | ||
| 653 | |a Agitation | ||
| 653 | |a Changes | ||
| 653 | |a Biological markers | ||
| 653 | |a Bootstrap method | ||
| 653 | |a Disease | ||
| 653 | |a Biomarkers | ||
| 653 | |a Medical treatment | ||
| 653 | |a Inflammation | ||
| 653 | |a Oxidative stress | ||
| 653 | |a Patients | ||
| 700 | 1 | |a Ruthirakuhan, Myuri |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 700 | 1 | |a Herrmann, Nathan |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 700 | 1 | |a Andreazza, Ana C. |u University of Toronto, Toronto, ON, Canada, | |
| 700 | 1 | |a Gallagher, Damien |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 700 | 1 | |a Verhoeff, Nicolaas Paul L.G. |u Baycrest Hospital, Toronto, ON, Canada, | |
| 700 | 1 | |a Kiss, Alex |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 700 | 1 | |a Black, Sandra E. |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 700 | 1 | |a Feldman, Oriel J |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 700 | 1 | |a Lanctôt, Krista L |u Sunnybrook Research Institute, Toronto, ON, Canada, | |
| 773 | 0 | |t Alzheimer's & Dementia |g vol. 21 (Dec 1, 2025) | |
| 786 | 0 | |d ProQuest |t Consumer Health Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3286852212/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3286852212/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |